Literature DB >> 8359897

Interaction of group B streptococcal opacity variants with the host defense system.

S H Pincus1, R L Cole, E Kamanga-Sollo, S H Fischer.   

Abstract

Group B streptococci (GBS) demonstrate high-frequency phase variation of colony opacity. Colony opacity is a function of chain length, with opaque colonies consisting of GBS that form longer chains. Because opaque variants do not grow on standard streptococcal media, the role of opacity variation in GBS infection has not been studied. We have isolated stable variants from type III GBS that are either transparent (variants 1.2 and 1.3) or opaque (variants 1.1 and 1.5). In this study, we evaluated the interactions of these variants with different components of the host immune system both in vitro and in vivo. Opaque GBS were less immunogenic than transparent GBS. Opaque GBS were more susceptible to killing by polymorphonuclear neutrophils (PMNs) and could induce a chemiluminescent response of PMNs in the absence of antibody (Ab) or complement. Transparent GBS did not induce neutrophil chemiluminescence in the absence of Ab and complement. However, in the presence of Ab and complement, transparent GBS induced a stronger chemiluminescent response than did opaque GBS. Scanning electron micrographs of PMNs and GBS demonstrated differences in the attachment and engulfment of the different variants by the PMNs as well as different effects of the GBS on the PMNs themselves. Interactions with complement were affected by GBS opacity as well, with opaque variant 1.1 initiating complement activation in the absence of any Ab. The virulence of the GBS opacity variants was studied in vivo by inoculation of graded numbers of GBS into newborn mice. Transparent variants 1.2 and 1.3 were most virulent, with variant 1.1 intermediate and variant 1.5 minimally virulent. However, in mixed infections, variant 1.5 greatly enhanced the virulence of small numbers of transparent GBS. These results indicate that the opacity status of GBS can influence the interaction between the GBS and the host immune system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359897      PMCID: PMC281075          DOI: 10.1128/iai.61.9.3761-3768.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Group B streptococcal opacity variants.

Authors:  S H Pincus; R L Cole; M R Wessels; M D Corwin; E Kamanga-Sollo; S F Hayes; W Cieplak; J Swanson
Journal:  J Bacteriol       Date:  1992-06       Impact factor: 3.490

3.  Protective efficacy of IgM monoclonal antibodies in experimental group B streptococcal infection is a function of antibody avidity.

Authors:  S H Pincus; A O Shigeoka; A A Moe; L P Ewing; H R Hill
Journal:  J Immunol       Date:  1988-04-15       Impact factor: 5.422

4.  Group B streptococcal infection in newborns: prevention at last?

Authors:  C J Baker
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

Review 5.  Summary of the workshop on perinatal infections due to group B Streptococcus.

Authors: 
Journal:  J Infect Dis       Date:  1977-07       Impact factor: 5.226

6.  Assessment of the virulence factors of group B streptococci: correlation with sialic acid content.

Authors:  A O Shigeoka; N S Rote; J I Santos; H R Hill
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

7.  Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.

Authors:  M S Edwards; D L Kasper; H J Jennings; C J Baker; A Nicholson-Weller
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

8.  Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule.

Authors:  M R Wessels; C E Rubens; V J Benedí; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

  9 in total
  6 in total

1.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization.

Authors:  J N Weiser; R Austrian; P K Sreenivasan; H R Masure
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

3.  Fine specificity and cross-reactions of monoclonal antibodies to group B streptococcal capsular polysaccharide type III.

Authors:  Seth H Pincus; Emily Moran; Grace Maresh; Harold J Jennings; David G Pritchard; Marianne L Egan; Ola Blixt
Journal:  Vaccine       Date:  2012-05-23       Impact factor: 3.641

4.  A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Authors:  Y Han; R P Morrison; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor.

Authors:  A Podbielski; O Blankenstein; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

Review 6.  Bacterial glycobiology: rhamnose-containing cell wall polysaccharides in Gram-positive bacteria.

Authors:  Michel-Yves Mistou; Iain C Sutcliffe; Nina M van Sorge
Journal:  FEMS Microbiol Rev       Date:  2016-03-13       Impact factor: 16.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.